

Supplementary Table 1. Baseline characteristics of participants with and without PASC

Characteristic	Participant (n = 79)	PASC (n = 41)	Non-PASC (n = 38)	p value
Age (yr)	57.9 ± 13.5	59.4 ± 13.9	56.2 ± 13.0	0.295
Sex, male	47 (59.5)	26 (63.4)	21 (55.3)	0.500
Vaccination status before diagnosis				
Unvaccinated (0 dose)	8 (10.1)	2 (4.9)	6 (15.8)	0.145
Partially vaccinated (1 dose)	3 (3.8)	2 (4.9)	1 (2.6)	> 0.999
Fully vaccinated (2 doses)	11 (13.9)	5 (12.2)	6 (15.8)	0.750
Fully vaccinated + monovalent booster	45 (57.0)	26 (63.4)	19 (50.0)	0.262
Fully vaccinated + bivalent booster	12 (15.2)	6 (14.6)	6 (15.8)	> 0.999
Predominant variant at diagnosis				
BA.5 (since Jul 4, 2022)	22 (27.8)	12 (29.3)	10 (26.3)	0.806
BA.2.75 (since Jan 16, 2023)	21 (26.6)	8 (19.5)	13 (34.2)	0.203
XBB (since Apr 24, 2023)	36 (45.6)	21 (51.2)	15 (39.5)	0.368
Number of infections ^{a)}				
Once	64 (86.5)	32 (80.0)	32 (94.1)	0.097
More than twice	10 (13.5)	8 (20.0)	2 (5.9)	
Underlying diseases ^{b)}				
Previously healthy	12 (15.6)	6 (15.0)	6 (16.2)	> 0.999
Diabetes mellitus	28 (36.4)	13 (32.5)	15 (40.5)	0.487
Cardiovascular disease	39 (50.6)	20 (50.0)	19 (51.4)	> 0.999
Pulmonary disease	11 (14.3)	8 (20.0)	3 (8.1)	0.196
Chronic liver diseases	7 (9.1)	1 (2.5)	6 (16.2)	0.051
Chronic kidney diseases	16 (20.8)	7 (17.5)	9 (24.3)	0.577
Malignancy	20 (26.0)	12 (30.0)	8 (21.6)	0.445
Transplantation	27 (35.1)	13 (32.5)	14 (37.8)	0.641
Autoimmune disease	0 (0.0)	0 (0.0)	0 (0.0)	
Any mental health problems	3 (3.9)	3 (7.5)	0 (0.0)	0.241
COVID-19 NIH severity at diagnosis ^{c)}				
Asymptomatic/presymptomatic	7 (9.9)	3 (8.1)	4 (11.8)	0.703
Mild	33 (46.5)	18 (48.6)	15 (44.1)	0.813
Moderate	14 (19.7)	8 (21.6)	6 (17.6)	0.770
Severe	9 (12.7)	4 (10.8)	5 (14.7)	0.729
Critical	8 (11.3)	4 (10.8)	4 (11.8)	> 0.999
Hospitalized patients' treatments ^{d)}				
Supplemental oxygen therapy	33 (61.1)	13 (50.0)	20 (69.0)	0.178
Steroid	41 (75.9)	18 (69.2)	23 (79.3)	0.537
Nirmatrelvir/ritonavir	1 (1.9)	1 (3.8)	0 (0.0)	0.473
Molnupiravir	3 (5.6)	2 (7.7)	1 (3.4)	0.598
Remdesivir	52 (96.3)	24 (92.3)	28 (96.6)	0.598
Tocilizumab	5 (9.3)	5 (19.2)	0 (0.0)	0.019
Baricitinib	5 (9.3)	1 (3.8)	4 (13.8)	0.355
Tocilizumab + baricitinib	3 (5.6)	1 (3.8)	2 (6.9)	> 0.999

Values are presented as mean ± standard deviation or number (%).

PASC, post-acute sequelae of COVID-19; NIH, National Institutes of Health.

^{a)}The infection history prior to participation in current study is uncertain in 5 individuals.

^{b)}Data not available in 1 individual per group.

^{c)}Data not available in 4 individuals per group.

^{d)}Data not available in 1 individual in PASC group.